Latest Breaking News On - Michail shipitsin - Page 1 : comparemela.com

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature

WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage.

United statesAlexandra santosMichail shipitsinCaroline wigerupPeter blume jensenDrug administrationAcrivon therapeutics incInternational conference on molecularExchange commissionMolecular targetsCancer therapeuticsPredictive precision proteomicsAcrivon predictive precision proteomicsPrivate securities litigation reform actMedia contactsNasdaq acrv

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

WATERTOWN, Mass., Sept. 19, 2023 Acrivon Therapeutics, Inc. , a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are.

United statesCaroline wigerupPeter blume jensenAlexandra santosMichail shipitsinDrug administrationAcrivon therapeutics incExchange commissionInternational conference on molecularMolecular targetsCancer therapeuticsPredictive precision proteomicsAcrivon predictive precision proteomicsPrivate securities litigation reform actMedia contacts

Acrivon Therapeutics Launches to Advance Clinical Oncology

Acrivon Therapeutics Launches to Advance Clinical Oncology
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Al iskandariyahKristina massonEric devroeMichail shipitsinErick gamelinJesper olsenAljanae reynoldsEli lillyJeremy bartonPeter blume jensenChris lemastersAlexandra santosMary rose kellerKelly gordonCompany lillyMd anderson cancer center